Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Visionary Pharma SGK1 inhibitor
- Development stage
- Preclinical
- Lead developer
- Thryv Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
Visionary Pharmaceuticals is developing a small molecule inhibitor of Serum and Glucocorticoid Regulated Kinase 1 (SGK1) for the treatment of autoimmune diseases and various cancers. SGK1 is a serine-threonine kinase that regulates Th17 cell differentiation by controlling IL-23 receptor expression; its inhibition is intended to modulate Th17-driven inflammatory responses. In oncology, SGK1 is a key mediator of tumor cell survival, invasiveness, and resistance to chemotherapy, particularly in triple-negative breast cancer, colorectal cancer, multiple myeloma, and prostate cancer. The program was developed using the company's proprietary BindingSIGHTS computational platform in collaboration with BioBlocks.
- Other names
- SGK1 inhibitor (Visionary Pharma)
02
Targets
SGK1
Beyond the preview
Go deeper on Visionary Pharma SGK1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Visionary Pharma SGK1 inhibitor.